TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
Journal Title
Cancer
Publication Type
epub ahead of print
Abstract
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Publisher
Wiley
Keywords
Tp53; acute myeloid leukemia (AML); cutoff; excess blasts; myelodysplastic syndrome (MDS); p53
Research Division(s)
Blood Cells And Blood Cancer
PubMed ID
36397669
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2022-12-13 03:13:02
Last Modified: 2022-12-14 01:07:31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙